WP3 is at the heart of PREMIO COLLAB, leading the international MONITOR Randomised Clinical Trial (MONITOR-RCT). This trial is the first of its kind to provide Level I evidence comparing FDG-PET/CT with conventional CT for monitoring treatment response in patients with metastatic breast cancer. By conducting this large-scale study, WP3 addresses a critical gap in evidence-based cancer care.
The trial goes beyond imaging comparisons—it evaluates patient-relevant outcomes, including overall survival, quality of life, treatment exposure, and cost-effectiveness. These insights are essential for shaping monitoring strategies that are not only clinically effective but also patient centred.
Through this work, WP3 generates the core clinical data that underpins PREMIO COLLAB’s mission: to establish robust, evidence-based pathways for treatment response monitoring in breast cancer care across Europe. Its findings will inform clinical practice, improve patient outcomes, and guide future policy decisions.